An FDA advisory panel this month recommended approval of an experimental treatment for peanut allergies, but writing in The Atlantic, James Hamblin questions whether the product is worth its likely $4,200 price tag—and flags research suggesting it may backfire for some patients.
Employee turnover is costly and can hurt productivity, but advances in data analytics are helping to identify specific leadership behaviors that cause workers to quit, Jon Christiansen, co-founder of Insights and Outcomes, writes for Harvard Business Review.
A federal judge on Tuesday vacated HHS' site-neutral payment policy that cuts Medicare payment rates for off-campus hospital facilities.